Skip to main content
Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc. — Investor Relations & Filings

Ticker · CMPX ISIN · US20454B1044 US Manufacturing
Open in API
Filings indexed 334 across all filing types
Latest filing 2026-05-05 Interim / Quarterly Rep…
Country US United States of America
Listing US CMPX

About Compass Therapeutics, Inc.

https://www.compasstherapeutics.com/

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company that develops proprietary antibody-based therapeutics. The company leverages its proprietary antibody discovery engine and in vitro/in vivo platforms to generate diverse antibody panels. This approach is based on a deep understanding of the tumor microenvironment, aiming to develop product candidates that optimize the immune system's anti-tumor response. The company's mission is to create transformative cancer therapies to improve patient outcomes.

Recent filings

Filing Released Lang Actions
10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-05 English
8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Current Report on Form 8-K filed with the SEC, furnishing a press release as Exhibit 99.1. It does not contain substantive financial data itself but is a regulatory compliance filing under the Securities Exchange Act. There is no actual earnings content in the text—only a reference to an attached press release—so it falls under the general regulatory filings category.
2026-05-05 English
ARS - Compass Therapeutics, Inc. (0001738021) (Filer)
Annual Report
2026-04-29 English
DEF 14A - Compass Therapeutics, Inc. (0001738021) (Filer)
Proxy Solicitation & Information Statement
2026-04-29 English
8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or updates that shareholders should know about between periodic reports. The content includes a press release and presentation about clinical trial data for a drug candidate, details about a webcast, and forward-looking statements. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit into categories like Earnings Release (ER) since it is not primarily a financial results announcement, nor is it a Management Report or Governance Information. The document is a regulatory filing announcing material events and disclosures, typical of the Regulatory Filings (RNS) category. The length and detail confirm it is not a brief announcement or a simple report publication notice. Therefore, the best classification is Regulatory Filings (RNS).
2026-04-27 English
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
Director's Dealing
2026-02-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.